慢性阻塞性肺病的新药研发进展.PDFVIP

现代药物与临床 Drugs Clinic 第 26 卷 第 5 期 2011 年 9 月 • 333 • • 综 述 • 慢性阻塞性肺病的新药研发进展 1 2 2* 2* 2 1 余 茜 ，闫少杰 ，黄汉忠 ，王平保 ，李树军 ，邓 超 1. 河南大学 药学院，河南 开封 475000 2. 天津药物研究院 化学制药部，天津 300193 摘 要：慢性阻塞性肺病患病率与死亡率高，得到越来越多的药物研发人员的关注。由于传统药物的不良反应与局限性，新 型药物的研发至关重要。现阶段研发的热点主要为新型抗胆碱药物、新一代超长效支气管扩张剂、新型磷酸二酯酶-4 抑制 剂、内皮素抑制剂、蛋白酶抑制剂等，其代表性药物分别为格隆溴铵、茚达特罗、罗氟司特、bimosiamose 、米地司坦等。 对慢性阻塞性肺病的新型药物的研发进展与前景进行综述。 关键词：慢性阻塞性肺病；抗胆碱药；支气管扩张剂；磷酸二酯酶-4 抑制剂；内皮素抑制剂；蛋白酶抑制剂 中图分类号：R974 文献标志码：A 文章编号：1674 - 5515(2011)05 - 0333 - 06 Study and development of new drugs on chronic obstructive pulmonary disease 1 2 2 2 2 1 YU Qian , YAN Shao-jie , HUANG Han-zhong , WANG Ping-bao , LI Shu-jun , DENG Chao 1. School of Pharmacy, Henan University, Kaifeng 475000, China 2. Centre for Chemical Pharmaceutical Research, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China Abstract: Given the high morbidity and mortality of chronic obstructive pulmonary disease (COPD), more drug developers get attention to it. Due to the adverse reaction and limitation of traditional medicines, the study and development of the new drug are very important. At present, hot spots in the research of main stage are new anticholinergic drugs, new generation of ultra-long-acting bronchodilators, new phosphodiesterase-4 (PDE-4) inhibitors, endothelin inhibitors, and protease inhibitors etc. The representative drugs are glycopyrrolate bromide, indacaterol, roflumilast, bimosiamose, midesteine, respectively. In this paper, the development and prospect of the new drug on COPD have been reviewed. Key words: chronic obstructive pulmonary disease (C